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Abstract A series of monomethoxy poly(ethylene gly-
col)–poly(lactide) (mPEG–PLA) diblock copolymers were
designed according to polymer–drug compatibility and
synthesized, and mPEG–PLA micelle was fabricated and
used as a nanocarrier for solubilization and oral delivery of
Cyclosporine A (CyA). CyA was efﬁciently encapsulated
into the micelles with nanoscaled diameter ranged from 60
to 96 nm with a narrow size distribution. The favorable
stabilities of CyA-loaded polymeric micelles were
observed in simulated gastric and intestinal ﬂuids. The in
vitro drug release investigation demonstrated that drug
release was retarded by polymeric micelles. The enhanced
intestinal absorption of CyA-loaded polymeric micelles,
which was comparable to the commercial formulation of
CyA (Sandimmun Neoral
), was found. These suggested
that polymeric micelles might be an effective nanocarrier
for solubilization of poorly soluble CyA and further
improving oral absorption of the drug.
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Introduction
The oral route is the most common route of drug admin-
istration in view of its convenience and patient acceptance,
even more so in the case of chronic therapies [1]. Many
existing and new therapeutic entities are characterized by a
low degree of water solubility leading to poor and erratic
oral bioavailability [2]. In order to overcome this hurdle,
several strategies such as micronization [3, 4], formation of
solid solutions [5], microemulsiﬁcation [6], and novel drug
delivery systems, including nanoparticles [7], lipid-based
vesicles [8, 9], have been proposed. Among these approa-
ches, polymeric micelles, constituted of amphiphilic block
copolymers, have attracted much attention in the decade
[10–12]. Generally, block copolymers with concentration
above the critical association concentration (CAC) self-
assemble into spherical polymeric micelles with a core–
shell structure in water: the hydrophobic segments aggre-
gate to form an inner core being able to accommodate
hydrophobic drugs with improved solubility by hydro-
phobic interactions; the hydrophilic shell consists of a
brush-like protective corona that stabilizes the micelles in
aqueous solution [13–15]. Polymeric micelles as novel
drug vehicles present numerous advantages, such as
reduced side effects of drugs, selective targeting, stable
storage, stable toward dilution, and prolonged blood cir-
culation time [15, 16]. Furthermore, polymeric micelles
possess a nanoscaled size with a narrow distribution. They
can protect drugs against premature degradation in vivo
owing to their core–shell architecture [17, 18]. More
importantly, polymeric micelles are fabricated according to
the physicochemical properties of drugs and the compati-
bility between the core of micelles and drug molecules
[15, 19]. From the pharmaceutical point of view,
these amphiphilic carriers can solubilize more poorly
Y. Zhang   X. Li   Y. Zhou   X. Wang   Y. Fan   Y. Liu (&)
Department of Pharmaceutics, School of Pharmaceutical
Sciences, Peking University, Xueyuan Road 38, Haidian District,
Beijing 100191, People’s Republic of China
e-mail: yanliu@bjmu.edu.cn
Y. Huang
Pharmaceutical Teaching Experiment Center,
School of Pharmaceutical Sciences, Peking University,
Beijing 100191, People’s Republic of China
123
Nanoscale Res Lett (2010) 5:917–925
DOI 10.1007/s11671-010-9583-4water-soluble drugs within their hydrophobic core than
most surfactant micelles. Since most of polymeric micelles
are intended to be administered intravenously [20], the
development of polymeric micelles via the oral route has
been attracted attention [16, 21, 22]. Francis et al. [9]
reported that the polymeric micelles exhibited high sta-
bility in gastric and intestinal ﬂuids and no signiﬁcant
cytotoxicity toward Caco-2 cells, and the apical-to-basal
permeability of Cyclosporine A (CyA) across Caco-2 cells
increased signiﬁcantly when loaded in polymeric micelles
compared to free CyA. However, the absorption enhance-
ment of drug loaded in polymeric micelles by oral delivery
to rats has remained elusive. These prompted us to inves-
tigate the suitability of polymeric micelles as carriers to
enhance the oral absorption of BCS Class II (i.e., low
solubility–high permeability) drugs.
In the present study, CyA which belongs to BCS Class
II was selected as a model drug. CyA is a highly lipo-
philic cyclic undecapeptide of 11 amino acids, and a
highly effective immunosuppressive agent which is
widely used in clinic for prevention of allograft rejection
after organ transplantation and treatment of autoimmune
disease [23–25]. Nevertheless, the oral bioavailability of
CyA is low and irregular [26] due to the large molecular
weight (1202 Da), low solubility in water (23 lg/mL
at room temperature) [27], very high lipophilicity
(log P = 2.92) [28], a substrate of P-glycoprotein, and
vulnerable to intestinal mucosa and liver P450 3A4. The
currently available oral formulation of CyA is in the form
of a microemulsion containing a high concentration of
Cremophor RH40 which has been reported to induce
undesirable side effects, such as nephrotoxicity and
induction of anaphylactic reactions in sensitized patients,
although the oral absorption of CyA was remarkably
enhanced. Consequently, there has been an urgent
requirement to design and develop a novel dosage form of
CyA aimed at decreasing the side effects of the current
formulation while preserving the bioavailability of the
drug.
The purposes of this study were to design and evaluate
CyA-loaded polymeric micelles in vitro. Therefore, mono-
methoxy poly(ethylene glycol)–poly(lactide) (mPEG–PLA)
with molecular weight of 2500, 5000, 10000, and 15000 Da
for PLA block were strategically designed and synthesized
by ring-opening polymerization of D,L-dilactide (D,L-LA) in
the presence of mPEG with molecular weight of 5000 Da,
respectively. The micelles preparation, CyA solubilization,
and micelles properties were investigated by the size mea-
surement, drug loading content (LC), encapsulation efﬁ-
ciency (EE), stability in gastrointestinal tract, and in vitro
drugrelease.IntestinalabsorptioninsituandexvivoofCyA-
loaded polymeric micelles was assessed, respectively.
Materials and Methods
Materials
Cyclosporine A (CyA) was kindly donated from Hangzhou
Zhongmei Huadong Pharmaceutical Co. Ltd., China.
Monomethoxy poly(ethylene glycol) with molecular
weight of 5000 Da (mPEG) and stannous 2-ethylhexanoate
were purchased from Sigma. 3,6-dimethyl-1,4-dioxane-
2,5-dione (D,L-lactide) was obtained from Daigang Bio-
logical Technology Co. Ltd., China. All other reagents
were of analytical grade, except those for HPLC assay
which were of HPLC grade.
Animals
Sprague-Dawley (SD) rats were obtained from Animals
Center of Peking University Health Science Center. All
animals were provided with standard food and water
ad libitum and were exposed to alternating 12-h periods of
light and darkness. Temperature and relative humidity were
maintained at 25 C and 50%, respectively. All care and
handling of animals were performed with the approval of
Institutional Authority for Laboratory Animal Care of
Peking University.
Prediction of Compatibility Between Polymers
and the Drug
Compatibility between polymers and the drug was pre-
dicted by interaction parameters calculated from partial
solubility parameter [29]. The solubility parameter was
obtained by Hansen’s approach, where the partial solubility
parameters (dd, dh, and dp) for the drug (CyA) and a range
of biodegradable polymers (PLA, PLGA, and PCL) were
calculated by the group contribution method (GCM) [30]
using Eqs. 1, 2, and 3 presented below.
dd ¼
P
Fdi
V
ð1Þ
dp ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ P
F2
pi
q
V
ð2Þ
dh ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ P
Fhi
p
V
ð3Þ
where Fdi, Fpi, and Fhi refer to the speciﬁc functional group
contributions van der Waals dispersion forces (Fdi), dipole–
dipole interactions (Fpi), and hydrogen bonding (Fhi),
respectively. While the interaction parameter between drug
and polymer was calculated according to Eqs. 4 and 5
presented below:
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Here, dd,p means the dd of polymer, dd,d the dd of drug
(CyA), dp,p the dp of polymer, dp,d the dp of drug (CyA),
dh,p the dh of polymer, dh,d the dh of drug (CyA), /p and /d
mean the volume fractions of polymer and drug,
respectively.
Synthesis and Characterization of mPEG–PLA
Copolymers
mPEG–PLA copolymers were synthesized as previously
described [20]. The synthesized diblock copolymers were
referred to as mPEGx–PLAy. x and y represented the
number-averaged molecular weight of the mPEG and PLA
block in kDa. For example, mPEG5–PLA2.5 consisted of a
5-kDa mPEG block connected to a 2.5-kDa PLA block.
The critical aggregation concentration (CAC) of mPEG–
PLA copolymer was determined by ﬂuorescence spec-
troscopy using pyrene (Fluka, [99%) as a hydrophobic
probe as previously reported [20]. The ﬂuorescence spectra
of pyrene were measured at varying copolymer concen-
trations using a Shimadzu RF-5301 PC ﬂuorescence
spectrometer at 25 C. The excitation wavelength was
adjusted to 392 nm, and the detection of ﬂuorescence was
performed at 333 and 335 nm. CAC was measured from
the onset of a rise in the intensity ratio of peak at 335 nm to
peak at 333 nm in the ﬂuorescence spectra of pyrene
plotted versus the logarithm of polymer concentration.
Preparation of mPEG–PLA Polymeric Micelles
mPEG5–PLA2.5 and mPEG5–PLA5 polymeric micelles
were prepared by rotary evaporation method [31]. In brief,
25 mg of mPEG–PLA was dissolved in 10 mL of methanol
followed by evaporation under vacuum at 60 C to form a
homogeneous ﬁlm. The resulting ﬁlm was dispersed in
10 mL of water at 60 C and then vortexed for 3 min. The
mixture was ﬁltered through a 0.45-lm ﬁlter (Millex-GV,
Millipore, USA) to obtain a clear and homogeneous
micellar solution. The CyA-loaded micelles were prepared
as described above except 25 mg of mPEG–PLA was
replaced by a mixture of 5 mg of CyA and 25 mg of
mPEG–PLA.
mPEG5–PLA10andmPEG5–PLA15polymericmicelles
were prepared by dialysis method [20]. In brief, 25 mg of
mPEG–PLA and 5 mg of CyA were dissolved in 3 mL of
dimethyl sulfoxide (DMSO). The solution was then intro-
duced into a dialysis bag (Spectrapor, MWCO = 3500) and
dialyzed against 1 L of distilled water, which was replaced
every 4 h in the course over 48 h. The micellar solution
obtained in the dialysis bag was then ﬁltered through a
0.45-lm ﬁlter (Millex-GV, Millipore, USA) to remove
nonencapsulated CyA. CyA-free micelles were produced by
the same method without adding CyA at the ﬁrst stage of the
preparation.
Particle Size Measurement
The average particle size and size distribution of polymeric
micelles were determined by dynamic light scattering
(DLS) (Zetasizer ZEN 3600, Malvern, UK). All DLS
measurements were performed with a scattering angle of
90 at 25 C after diluting the micellar solution to an
appropriate volume with water. The results were the mean
values of three samples.
Determination of Encapsulation Efﬁciency and Drug
Loading Content
In order to determine drug loading content (LC, w/w %)
and entrapment efﬁciency (EE, w/w %) of micelles, CyA-
loaded polymeric micelles solution was freeze-dried and
then dissolved in methanol and CyA content in micelles
was determined on a Shimadzu series HPLC system (Shi-
madzu LC-10AT, Kyoto, Japan) equipped with a UV
detector (Shimadzu SPD-10A) and reversed phase column
(ODS C18, 5 lm, 4.6 mm 9 250 mm, Dikma, China). The
mobile phase consisted of acetonitrile/water (90/10, v/v)
and was pumped at a ﬂow rate of 1.0 mL/min. The
detection wavelength was 210 nm. The column tempera-
ture was set to 70 C. The LC and EE of the micelles were
then calculated based on the following formula:
LC ð%Þ
¼
mass of CyA extracted from freeze-dried micelles
total mass of freeze-dried micelle
  100%;
EE ð%Þ
¼
mass of CyA extracted from freeze-dried micelles
total mass of CyA loaded micelle initially used
  100%:
Stability of CyA-Loaded Polymeric Micelles in Simulated
Gastric and Intestinal Fluids
The stability of CyA-loaded polymeric micelles in simu-
lated gastric ﬂuid (SGF) and simulated intestinal ﬂuid (SIF)
for a period of 12 h was evaluated from the changes of EE
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the micelles samples in SGF or SIF at 37 C, respectively.
The EE and particle size of micelles were determined as
described earlier.
In Vitro Release of CyA from Micelles
One milliliter of micelles solution with known CyA content
was placed into a dialysis bag with molecular weight cut-
off of 50 kDa. The dialysis bag was immersed into a ﬂask
containing 30 mL of release medium (SGF or SIF) con-
taining 30% (v/v) ethanol (sink condition) which was kept
in a constant temperature shaking water bath at 37 C and
100 rpm. At predetermined time intervals, aliquots (1 mL)
of the release medium was taken and replaced by fresh
medium. The content of CyA in the medium was measured
by HPLC method as described above. The cumulative
release percentage of CyA was calculated.
Intestinal Absorption
Male SD rats weighing 200 ± 20 g were used for this
research. All animals were housed with free access stan-
dard food and tap water, and exposed to alternating 12 h
periods of light and darkness. Temperature and relative
humidity were maintained at 25 C and 50%, respectively.
After an acclimatization period of 2 days, the rats were
fasted for 12 h but allowed free access to water prior to the
experiments. Rats were anaesthetized via intraperitoneal
injection of 15% w/v urethane at a dose of 1.5 g/kg and a
laparotomy was performed.
In situ rat perfusion experiments [32–35] The abdominal
cavity was opened, and a segment of the ileum was exposed.
The segment was ﬂushed with 50 ml of warmKrebs–Ringer
buffer solution [KRB, pH 7.4, composed of (in mM): NaCl
111.9, KCl 5.0, CaCl2 1.2, MgCl2 1.2, NaH2PO4 0.4,
Na2HPO41.6, NaHCO3 25.0, NaGlutamate 4.9, NaPyruvate
4.9, Na2Fumarate 5.4, glucose 11.5] to remove the luminal
contents and then ﬂushed with air to minimize the amount
of luminal ﬂuid. These rats were placed in a warm table for
the absorption studies after surgery.
The perfusion solution was prepared using 1 mg/mL of
CyA-loaded polymeric micelles (mPEG5-PLA5) or Sand-
immun Neoral
 in KRB containing 3-mg/mL phenol red.
Phenol red acted as a nonabsorbable marker in the luminal
medium to correct the appreciable inﬂuence of the secretion
or absorption of water on CyA content during the experi-
ment. A recirculating system was constructed by connecting
a small reservoir containing 40 mL of stirring perfusion
solution kept at 37 C with the inlet cannula and by
directing the ﬂow from the outlet cannula back to the res-
ervoir. The perfusion pump (BT300-300M, Lange, Co, Ltd.
China) was utilized to drive the perfusate at a rate of
2 mL/min through the inlet cannula into the intestinal
segment. 0.5 mL of perfusate samples were collected and
replaced by fresh KRB containing 3-mg/mL phenol red at
0.25, 0.5, 1, 2, 3, 4, 6, 8 h after perfusion. The CyA con-
centration in the perfusate samples was measured by HPLC
method as described above, and the phenol red concentra-
tion was determined using UV spectrophotometer (Agilent
8453, Agilent Technologies, UK) at 558 nm.
Ex vivo experiments [29, 36] A laparotomy was per-
formedandsegmentofileumwereremoved andusedforthe
everted gut sac technique. In brief, the ileum was rinsed
twice with saline solution (0.9% NaCl) atroom temperature.
Then the specimen was put into oxygenated Tyrode solution
[pH 7.4, composed of (in mM): NaCl 115, KCl 2.7, CaCl2
1.8, MgCl2 1.1, NaH2PO4 0.4, Na2HPO4 1.6, NaHCO3 12.7,
glucose 5.6] immediately at 37 C. Then the intestine was
gently everted over a glass rod and divided into 5-cm sacs
which were ﬁlled with fresh oxygenated Tyrode solution
using silk suture. The sacs were incubated in gentle shaking
oxygenated Tyrode solution containing CyA-loaded poly-
meric micelles or Sandimmun Neoral
 for 120 min.
Thereafter, the Tyrode solution with and without sacs was
collected. The content of remainingCyA in the medium was
measuredbyHPLCmethod asdescribedabove.Themassof
theboundCyAwasdeterminedbysubtractionofthemassof
remaining CyA in the medium from the initial mass of CyA
and reported as percent binding:
Bindð%Þ
¼ 1 
massof CyAremaininginthe medium
total massof CyAloadedmicelle initially used
  
 100%:
The commercial formulation of CyA, Sandimmun
Neoral
, was also tested as control.
Statistical Analysis
All data were expressed as mean standard deviation (SD)
unless particularly outlined. The statistical signiﬁcance of
differences among more than two groups was determined
by one-way ANOVA by the software SPSS 13.0. A value
of p\0.05 was considered to be signiﬁcant.
Results and Discussion
Compatibility Between Polymers and the Drug
The compatibility between a drug and polymer is known to
be one of the key factors in determining the effectiveness
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the compatibility between a drug and polymer, the higher
the loading content and the slower the drug release as well.
Thus, the compatibility between a drug and polymer which
was referred to miscibility and interaction has been shown
to be of importance in the design of a wide range of
delivery systems including polymeric micelles.
Thermodynamic criteria for the mutual miscibility of
two substances is based on the Gibbs energy of mixing
(DGM) which is deﬁned by the following equation:
DGM = DHM – TDSM. The two substances are said to be
mutually soluble if DGM is negative. Equation 5 was used
to calculate DHM considering it takes into account all
forces: Van der Waals dispersion, dipole–dipole, and
hydrogen bonding. A smaller DHM indicated a stronger
interaction between two substances. As shown in Eq. 5, the
value of DHM mainly depends on that of D, indicating that
the compatibility between a drug and polymer can be
evaluated by D or DHM which is referred as interaction
parameter. The interaction parameters of CyA with various
polymers calculated by GCM were listed in Table 1. The
results showed that the interaction parameter of CyA with
PLA was lower than those of other drug–polymer pairs,
suggesting that PLA was identiﬁed to be more compatible
to CyA among the three polymers. Based on the results
calculated, PLA was therefore selected as the hydrophobic
segments of the amphiphilic copolymer for the subsequent
studies.
Synthesis and Characterization of mPEG–PLA
Copolymers
mPEG–PLA copolymers were synthesized by ring-opening
polymerization of D,L-dilactide by using mPEG as initiator.
Various chain lengths of PLA in the copolymers were
obtained by modulating the feed ratio of mPEG and
Table 1 The interaction parameters for CyA and various polymers
Polymer D (J/cm
3) DHM (J)
PLA 4.03 0.78
PLGA (LA/GA, 50:50) 5.37 2.16
PCL 5.68 2.97
Fig. 1
1H-NMR spectrum of
mPEG5–PLA2.5 copolymer
Nanoscale Res Lett (2010) 5:917–925 921
123D,L-dilactide. Figure 1 showed the
1H-NMR spectrum of
mPEG5–PLA2.5 which was representative for all synthe-
sized mPEG–PLAs: the peak at 3.6 ppm corresponded to
methylene protons (–OCH2CH2–) in mPEG blocks, signals
at 1.5 ppm could be attributed to the hydrogen atoms of
CH3O-groups for PLA segments, respectively [33]. The
ratio of number-averaged molecular weight (Mn) of the
mPEG to PLA blocks of each copolymer was calculated
from the
1H-NMR data. In brief, the ratio of the number of
methylene protons (–OCH2CH2–) in PEG and (–OCH3)i n
PLA was equally as the ratio of integral value of H in 3.6
and 1.5 ppm. The molecular weight of mPEG was known
as 5000 and the molecular weight of PLA linked to mPEG
would be known as listed in Table 2. It could be seen that
the copolymers could be synthesized reliably.
Micelle formation requires the balance between the
attractive interactions of the insoluble PLA moieties and
the repulsive interactions of the soluble PEG segments.
In effect, PEG moderates the association of PEG–PLA
molecules, leading to micelle formation. When the PEG
proportion in the copolymer chains is too low, PEG seg-
ments cannot moderate the association of the separating
PLA–PEG molecules, and macroscopic agglomerates are
formed. In line with these observations, Shin et al. reported
that micelles could not be formed by a poly(ethylene gly-
col)/epsilon-caprolactone copolymer with a too-high cap-
rolactone content (70.7% by weight) [37]. Moreover, a low
CAC is an important feature for the application of these
micelles in drug delivery because it assures that micelles
will be stable in vivo, where considerable dilution takes
place. Polymeric micelles can be formed only when the
block copolymer concentration is higher than CAC which
characterizes the micelle stability. The micellization
behavior of the synthesized mPEG5–PLAy copolymers
was therefore investigated. Table 2 summarized the
CAC values of various synthesized mPEG–PLA diblock
copolymers ranging from 1.08 9 10
-7 to 3.07 9 10
-7
mol/L. These values appeared much lower than those of
low molar mass surfactants, indicating that micelles formed
from mPEG–PLA copolymers as drug carriers could pre-
serve stability without dissociation after dilution [13, 38],
which was of major interest for oral administration.
Moreover, the hydrophilicity of mPEG–PLA copolymers
mainly depending on the mass ratio of mPEG/PLA or
mPEG content had much inﬂuence on the CAC value [39].
As shown in Table 2, the CAC values of copolymers
appeared to decrease with increasing of PLA block length.
mPEG5–PLA15 had longer hydrophobic PLA block and,
thus, could self-assemble more easily to form micelles,
leading to lower CAC value. This was consistent with our
previous report [20].
Characterization of mPEG–PLA Polymeric Micelles
The polymeric micelles were evaluated by particle size,
encapsulation efﬁciency, and drug loading content. The
mean particle size and size distribution of CyA-loaded
polymeric micelles were determined by DLS. The mean
diameter ranged from 60 to 96 nm for CyA-loaded
micelles with narrow distributions (Table 2). It appeared
that the micelle size gradually increased with increasing of
the length of PLA chains, which was consistent with our
previous report [20]. This result was also in agreement with
the characteristic of amphiphilic copolymeric micelles, i.e.,
the shorter the hydrophobic block length, the smaller the
micelles. It might be attributed to the fact that it is difﬁcult
to form compact polymeric micelles for amphiphilic
copolymers with longer hydrophobic chain length.
The encapsulation efﬁciency (EE) and loading content
(LC) of micelles were presented in Table 2. It could be
found that the LC and EE of CyA-loaded mPEG5–PLA5
polymeric micelles were signiﬁcantly higher than those of
others (p\0.05 for LC and p\0.01 for EE, respectively).
Notably, the results were not the general trend that LC and
EE of polymeric micelles increased with increasing
hydrophobic chain length. This ﬁnding may be assigned to
the factors contributing to LC and EE. In general, LC and
EE depend on the composition of the copolymers [38, 40,
41], the length of hydrophobic block [42], initial diblock
copolymeric concentration or the feed weight ratio of the
drug to the copolymer, the solvent used in formulation
process[41, 43] and micelle preparation method [44, 45],
Table 2 Characterization of mPEG5–PLAy copolymers and polymeric micelles
Copolymers Mn (PLA) CAC (10
-7 mol/L) CyA loaded LC (%) EE (%)
d (nm) PDI
mPEG5–PLA2.5 2249 3.07 60.1 ± 8.2 0.23 12.1 ± 0.8 44.0 ± 3.0
mPEG5–PLA5 4802 1.99 71.9 ± 0.4 0.19 15.2 ± 1.1 77.9 ± 4.1
mPEG5–PLA10 9247 1.57 89.0 ± 0.5 0.20 10.7 ± 1.5 33.1 ± 2.1
mPEG5–PLA15 15825 1.08 95.2 ± 1.2 0.23 9.7 ± 0.2 10.9 ± 0.2
d and PDI represent the average diameter and the polydispersity index (PDI) of micelles in aqueous solution, respectively
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and mPEG5–PLA5 polymeric micelles were prepared by
rotary evaporation method, whereas mPEG5–PLA10 and
mPEG5–PLA15 polymeric micelles were prepared by
dialysis method. In general, the LC and EE of polymeric
micelles prepared by rotary evaporation method are higher
than those of polymeric micelles prepared by dialysis
method [45–47]. The results in current study were in
agreement with this trend. Moreover, for mPEG5–PLA2.5
and mPEG5–PLA5 polymeric micelles, the LC and EE
were the general trend, i.e., increased with increasing
hydrophobic chain length, however, the results were
opposite for mPEG5–PLA10 and mPEG5–-PLA15 poly-
meric micelles, as reported that LC and EE decreased with
increasing hydrophobic chain length when polymeric
micelles were prepared by dialysis method due to enhanced
water-insolubility of copolymers [48].
Stability Studies of CyA-Loaded Polymeric Micelles
in Simulated Gastric and Intestinal Fluid
The particle size and entrapment efﬁciency of micelles
incubated in SGF and SIF at 37 C were determined at
predetermined time intervals. As shown in Fig. 2, there
was no signiﬁcant change in either EE or particle size of
micelles with time from 0 h until 12 h, indicating that the
CyA-loaded polymeric micelles were stable in SGF and
SIF at 37 C for a long enough time. Further, the micelles
appeared equally stable in these two media for the time
period studied.
In addition, in the case of release experiment, it was
found that no CyA was detected in SGF or SIF at the end of
24 h, which might be due to the fact that the amount of
released drug was probably below the detection limit
of HPLC method. This might be advantageous in micelle
stability aspect [49]. Since micelles retained almost all the
incorporated CyA, the formulations had high stability, and
drug in micelle core would be protected from biological
degradation in GI before reaching absorption site. Thus,
from a stability perspective, these micelles appear to be
suitable candidates as an oral dosage form of CyA.
In Vitro Release of CyA from Micelles
When developing oral colloidal delivery systems for highly
hydrophobic drugs such as CyA, it is important to ade-
quately control the release rate to avoid precipitation upon
dilution in the stomach and maximize the absorption in the
small bowel. Therefore, the in vitro release of CyA from
polymeric micelles at different release medium was eval-
uated. Prior to conducting these release assays, it was
veriﬁed that CyA could freely diffuse through the dialysis
membrane (Fig. 3), and that sink condition was respected
by addition of 30% (v/v) ethanol in the release medium
while preserving the stability of polymeric micelles (data
not shown). In addition, the release property of CyA from
polymeric micelles in SGF did not differ from that in SIF
(data not shown), indicating that the release media had no
effect on the release of CyA from micelles. Consequently,
SIF was chosen as the release medium for the subsequent
release studies.
As shown in Fig. 3, 85% of CyA was released from
polymeric micelles within 24 h. The comparison of the
proﬁles of CyA release from the micelles and the solution
showed that the entrapment of CyA in the mPLA–PEG
micelles could signiﬁcantly retard its in vitro release
[16,50].Assuming thatsimilar sustained release also occurs
in vivo, this would provide the micelles the necessary time
required to exert their inﬂuence on drug bioavailability. In
addition, the release rate of CyA from mPEG5–PLA10
micelles was comparable to that from mPEG5–PLA15
micelles and faster than that from mPEG5–PLA2.5 and
Fig. 2 Variation of size (a) and entrapment efﬁciency (EE) (b)o f
CyA-loaded polymeric micelles with incubation time in SGF and SIF
at 37 C( n = 3) Fig. 3 Release proﬁles of CyA from mPEG–PLA polymeric micelles
in SIF at 37 C, respectively (n = 3)
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observed in the release proﬁles of the former. These might
be attributed to the fact that it is difﬁcult to form compact
polymeric micelles for amphiphilic copolymers with longer
hydrophobic chain length. Furthermore, polymeric micelles
prepared by dialysis method were looser than those pre-
pared by other methods. In addition, as compared to the
CyA-loaded mPEG5–PLA2.5 micelles, mPEG5–PLA5
micelles released markedly slower, which was consistent
with previous report [51]. This might be assigned to the
relatively bigger size of mPEG5–PLA2.5 micelles [52] and
stronger interaction between CyA and longer hydrophobic
chain of PLA. As reported earlier, the release of a drug from
polymeric micelles could be affected by the level of drug
encapsulation, its physical state, the nature of the polymer
and the level of polymer-drug compatibility [30, 53, 54].
Based on the results of CyA-loading and CyA-release
experiments, mPEG5–PLA5 polymeric micelles were
therefore selected for the subsequent studies.
Intestinal Absorption
The absorption proﬁles of CyA-loaded mPEG5–PLA5
polymeric micelles and commercial formulation (iSan-
dimmun Neoral
) were evaluated, respectively. As shown
in Fig. 4, the cumulative absorption percentage of CyA-
loaded polymeric micelles was higher than that of Sand-
immun Neoral
 at each determined time point. For
example, the cumulative absorption percentage of CyA-
loaded polymeric micelles was higher than 65% within the
ﬁrst 2 h while it was lower than 60% for Sandimmun
Neoral
. This absorption enhancement of CyA-loaded
polymeric micelles compared with Sandimmun Neoral

was further conﬁrmed by the everted sac experiment which
showed that the binding percentage (59.93 ± 2.17%) of
CyA-loaded polymeric micelles was signiﬁcantly higher
than that of Sandimmun Neoral
 (51.24 ± 5.79)
(p\0.05). The absorption enhancement of CyA by poly-
meric micelles could be attributed to the fact that the sol-
ubility of CyA which belongs to BCS class II drug (i.e.,
low solubility–high permeability) according to BCS was
enhanced and the nanoscaled size of micelles would make
the micelles adhere to the intestinal mucosal epithelial to
get a longer absorbed time.
Earlier investigation demonstrated that polymeric
micelles transported Caco-2 cell monolayers neither by the
paracellular route nor by M-cells. One possible mechanism
was that polymeric micelles might undergo an active
transport that probably involved endocytosis, which was
conﬁrmed by using FAE cell model which mimics M-cells
and are specialized in the uptake of macromolecules and
particles via transcytosis [55]. Further experiments should
be conducted using Caco-2 cell model due to the fact Caco-
2 cells were considered to be a representative model for
assessing intestinal uptake of drugs, which are in progress
by our group.
Conclusions
mPEG–PLA micelles were designed and prepared to
encapsulate CyA, a highly lipophilic drug. The results of
the present study demonstrated that polymeric micelles
sustained the drug release, and the CyA-loaded mPEG–
PLA micelles were stable in gastrointestinal tract. As
anticipated, the intestinal absorption of CyA was signiﬁ-
cantly improved by polymeric micelles and comparable to
that of Sandimmun Neoral
. These ﬁndings indicated that
polymeric micelles would be a promising nanocarrier for
improving the oral absorption of poorly absorbable drugs
although the mechanism of polymeric micelles to cross
intestinal barrier is still uncertain.
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